ArticleScientific reports2025
Impact of dietary Biocide clay on growth, physiological status, and histological indicators of the liver and digestive tract in Nile tilapia (Oreochromis niloticus).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-organ histological assessment of Agrococcus sp. RKDAS_1 reveals tissue-level biocompatibility in Oreochromis niloticus.Journal of molecular histology · 2026Review
- Dietary date palm seed nanoparticles modulate biochemical parameters, immune-antioxidant gene expression, and histomorphology in Nile tilapia.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of Biocide, containing silicon tetrahedrons and organic acids, on growth performance, feed utilization, immune response, and oxidative status in Nile tilapia (Oreochromis niloticus). A total of 300 Nile tilapia fingerlings (initial weight: 3.55 ± 0.01 g) were distributed across 15 tanks and fed diets containing 0.0 (control), 0.25, 0.5, 1, and 2 g kg⁻¹ Biocide for 90 days, with three replicate tanks per treatment. Biocide is enriched with organic acids (fumaric acid and citric acid) and amino acids (glutamine, tyrosine, methionine, serine, and threonine). Fish fed Biocide-supplemented diets demonstrated significantly improved growth performance, with the highest weight gain, feed conversion ratio, and protein efficiency ratio observed in the 1 g kg⁻¹ group. Survival rates did not differ significantly among treatments. Whole-body crude protein content peaked in the 1 g kg⁻¹ group, while moisture, lipid, and ash contents remained unchanged. Hematological parameters, including red blood cell count, hemoglobin concentration, and packed cell volume, improved significantly. Serum lipid profiles showed reduced cholesterol, triglycerides, low-density lipoprotein, and very-low-density lipoprotein levels, alongside increased high-density lipoprotein levels, particularly in the 1 g kg⁻¹ group. Antioxidant enzyme activities (catalase, glutathione peroxidase) and total antioxidant capacity were significantly elevated in the liver and intestine, while malondialdehyde levels decreased. Digestive enzyme activities (amylase, lipase, and protease) were markedly enhanced. Histopathological analysis revealed improved liver, stomach, and intestinal morphology, including increased mucous secretion and enhanced intestinal villi structure, in fish fed 1 g kg⁻¹ Biocide. In conclusion, Biocide supplementation, particularly at 1 g kg⁻¹, significantly improved growth performance, feed utilization, immune function, and antioxidant capacity in Nile tilapia. Notably, the findings highlight Biocide's primary mode of action on gut health, underscoring its potential as a dietary additive for improving aquaculture productivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.